AHA & AstraZeneca Push for Uptake of SGLT2 Inhibitors with TRANSLATE-HF Program

With the efficacy and safety of SGLT2 inhibitors well-established, focus has now shifted to understanding the real-world use and applicability of these revolutionary agents. Among the multitude of ongoing programs and studies examining these topics is TRANSLATE-HF, which is a program commissioned by the American Heart Association (AHA) in collaboration with AstraZeneca focused on optimizing evidence-based treatment for patients with heart failure.

In the first study from TRANSLATE-HF, which is composed of 6 studies in total, investigators sought to evaluate the generalizability of DAPA-HF eligibility and the US FDA label for dapagliflozin to heart failure patients in the US. Using these criteria and applying them to the AHA’s Get With the Guidelines-Heart Failure Registry, investigators determined 4 of 5 heart failure patients met criteria for receiving dapagliflozin. Presented at the AHA Scientific Sessions 2020, results of this study confirmed what many had already suspected—a large percentage of patients could benefit from receiving an SGLT2 inhibitor.

While the first study provides valuable insight, it has also bolstered interest in TRANSLATE-HF and the remaining data to come from the program. For more information on TRANSLATE-HF, the results of the first study presented at AHA 2020, and what tells us about SGLT2 inhibitor use, Practical Cardiology reached out to the study’s lead investigator Muthiah Vaduganathan, MD, MPH, a cardiologist at Brigham and Women’s Hospital, to take part in AHA 2020 House Call.

Timestamps:
What is TRANSLATE-HF? - 0:10

Were you surprised by the results? - 2:10

Can you share details on upcoming studies? - 3:30

The study mentioned in this article, “Generalizability of the US FDA Label for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in the GWTG-HF Registry,” was presented at AHA 2020.